quinuclidines has been researched along with Adverse Drug Event in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borroni, ME; Hansen, V; Jordan, K; Karthaus, M; Rizzi, G; Rossi, G; Rugo, HS; Schwartzberg, L | 1 |
| Bonizzoni, E; Celio, L; Di Nicola, M; Gianni, AM; Magni, M; Mirabile, A | 1 |
| Abramovitz, RB; Gaertner, KM | 1 |
| Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE | 1 |
| Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E | 1 |
| Aapro, M; Gralla, RJ; Hesketh, PJ; Jordan, K; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Arata, K; Azuma, K; Fujiwara, K; Goto, K; Hashimoto, H; Hayashi, T; Kogure, Y; Matsui, R; Nagase, S; Nakao, M; Nogami, N; Ohyanagi, F; Seki, N; Shimada, T; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Yamamoto, N; Yamanaka, T | 1 |
| Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M | 1 |
| Bianchini, C; Bonanno, V; Crescimanno, A; Musso, M; Perrone, T; Polizzi, V; Porretto, F; Scalone, R | 1 |
| Boucher, JF; Clemence, RG; Conder, GA; Sedlacek, HS | 1 |
| Boucher, JF; Clemence, RG; Conder, GA; Eagleson, JS; Kincaid, K; Ramsey, DS; Watkins, JA | 1 |
| Ardizzoia, A; Bajetta, E; Bertolini, A; Bichisao, E; Buonadonna, A; Capobianco, AM; Cavanna, L; Celio, L; Denaro, A; Fabi, A; Frustaci, S; Isa, L; Piazza, E | 1 |
| Hussar, DA | 2 |
| Cardozo, L; Castro-Diaz, D; Gittelman, M; Huang, M; Ridder, A | 1 |
| Brames, MJ; Bubalo, J; Cullen, MT; Dreicer, R; Einhorn, LH; Nichols, CR | 1 |
| Wick, JY | 1 |
2 review(s) available for quinuclidines and Adverse Drug Event
| Article | Year |
|---|---|
The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2016 |
Xerostomia: causes and treatment.
Topics: Autoimmune Diseases; Bone Marrow Transplantation; Drug-Related Side Effects and Adverse Reactions; Humans; Pilocarpine; Quinuclidines; Saliva; Thiophenes; Xerostomia | 2007 |
10 trial(s) available for quinuclidines and Adverse Drug Event
| Article | Year |
|---|---|
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studie
Topics: Administration, Oral; Anthracyclines; Antiemetics; Aprepitant; Cyclophosphamide; Dexamethasone; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Pyridines; Quinuclidines; Treatment Outcome | 2019 |
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2014 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infant; Internationality; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Transplantation Conditioning; Treatment Outcome; Vomiting; Young Adult | 2017 |
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Hormonal; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Hematologic Neoplasms; Humans; Isoquinolines; Italy; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2009 |
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
Topics: Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Confidence Intervals; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Risk Assessment; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Muscarinic Antagonists; Population; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Male; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
5 other study(ies) available for quinuclidines and Adverse Drug Event
| Article | Year |
|---|---|
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Topics: Adult; Aged; Antiemetics; Biomarkers, Pharmacological; Dexamethasone; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
Topics: Animals; Cross-Over Studies; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Male; Motion Sickness; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Topics: Administration, Oral; Animals; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Injections, Subcutaneous; Male; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
New drugs 06, part I.
Topics: Acamprosate; Adenine Nucleotides; Alcohol Deterrents; Amyloid; Analgesics, Non-Narcotic; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Benzofurans; Clofarabine; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Exenatide; Fibroblast Growth Factor 7; Guanine; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lipopeptides; Lipoproteins; Macular Degeneration; Micafungin; omega-Conotoxins; Patient Education as Topic; Peptides; Peptides, Cyclic; Piperazines; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Stomatitis; Taurine; Tetrahydroisoquinolines; Urinary Incontinence; Venoms | 2006 |